Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Connor Johnson, MD, Massachusetts General Hospital & Harvard Medical School, Boston, MA, outlines the results of a retrospective analysis evaluating the impact of CAR T-cell therapy on healthcare utilization and end-of-life outcomes. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.